CRISPR Therapeutics AG (CRSP) Return on Capital Employed (2016 - 2026)

CRISPR Therapeutics AG has disclosed Return on Capital Employed across 11 years of filings, most recently posting 27.4% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 27.4%, down 464.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 27.4% (down 464.0% YoY), and the FY2025 annual result was 31.58%, down 986.0% from the prior year.
• Return on Capital Employed came in at 27.4% for Q1 2026 at CRISPR Therapeutics AG, up from 31.55% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 12.17% in Q1 2022 to a low of 31.55% in Q4 2025.
• The 5-year median for Return on Capital Employed is 22.76% (2025), against an average of 21.2%.
• Peak annual rise in Return on Capital Employed reached 3401 bps in 2022, while the deepest fall reached 4548 bps in 2022.
• CRISPR Therapeutics AG's Return on Capital Employed stood at 30.92% in 2022, then jumped by 65 bps to 10.86% in 2023, then slumped by 99 bps to 21.59% in 2024, then slumped by 46 bps to 31.55% in 2025, then advanced by 13 bps to 27.4% in 2026.
• The last three Return on Capital Employed figures came in at 27.4% (Q1 2026), 31.55% (Q4 2025), and 28.46% (Q3 2025), per Business Quant data.